Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Commercial Sponsor
Deciphera Pharmaceuticals LLC
Summary
In this trial, patients will be randomised to receive 150mg
of oral DCC-2618 or 50mg of oral sunitinib daily.
To join this trial, patients must have a histologic diagnosis of GIST and have progressed on imatinib or have documented intolerance to imatinib therapy.